Sinovac applies for conditional marketing authorization of COVID-19 vaccine
BEIJING -- Beijing-based Sinovac Life Sciences Co., Ltd. on Wednesday filed an application with Chinese authorities for conditional marketing authorization of its anti-COVID-19 vaccine CoronaVac.
The application has been received by the National Medical Products Administration (NMPA), according to Sinovac Biotech Ltd., which has a majority stake in the vaccine producer.
The inactivated vaccine CoronaVac has made progress in phase three clinical trials overseas, showing a good level of safety after inoculation, according to a company statement.
Fourteen days after the inoculation of two doses of CoronaVac, the effectiveness of the vaccine in protecting against diseases caused by COVID-19 has met the relevant technical standards laid out by the World Health Organization and the requirements of the NMPA, the statement said.
- Summer months transform Tianjin's Qilihai Wetland into an ecological showcase
- Linyi meets RCEP: Connecting regional markets, sharing global goods
- Students from both sides of Taiwan Strait compete in a friendly dragon boat race
- China activates emergency response to flooding in 3 provincial-level regions
- China strengthens animal-attack regulations with updated law
- South Korean trade rep highlights RCEP expo for intl co-op
